Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04514354
Other study ID # H14-183HH
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2015
Est. completion date January 2016

Study information

Verified date August 2020
Source University of Connecticut
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sudden cardiac death (SCD) is the number one cause of on-duty firefighter death. It is most likely to occur in adults who are not physically fit that engage in sudden vigorous exercise. Cardiorespiratory physical fitness (also known as aerobic fitness) is a major heart disease risk factor. In FIT and FIRED UP, the study investigators looked at the influence of cardiorespiratory fitness on blood pressure, heart rate, and other heart markers taken from the blood before and after a vigorous exercise test to maximal effort among firefighters from a local fire department in Connecticut. In addition, the investigators also looked at how lifestyle habits including physical activity, nutrition, stress, and sleep may influence our findings. It was hypothesized that aerobically fit firefighters would show less stress on their heart than unfit firefighters.


Description:

The primary purpose of this study was to examine the influence of cardiorespiratory fitness on the acute release of SCD biomarkers and other cardiovascular disease (CVD) risk factors at rest and in response to a bout of maximal physical exertion among 21 firefighters from a local fire department in Connecticut. The study investigators hypothesized that firefighters that are aerobically fit will have lower levels of biomarkers of SCD and a more favorable CVD risk factor profile at rest and in response to a maximal physical effort than firefighters that are not aerobically fit.

FIT and FIRED UP is based on the theoretical foundation of the health belief and social cognitive models of health behavior change which have been shown effective in improving diet and exercise behaviors in firefighters. Specifically, the investigators sought to identify job-specific risk factors for SCD and CVD in firefighters in order to better tailor an intervention that focuses on providing information, reducing barriers to changing unhealthy behaviors, reducing stress, and increasing firefighter efficacy to engage in healthier behaviors.

All eligible members of the fire department were invited to participate in the study. Visit 1 included an orientation health education session at the fire department in which the study investigators delivered a lecture on physical activity and "heart healthy" habits. Interested subjects were able to review the informed consent and questionnaires.

Subjects completed and signed the informed consent at the beginning of Visit 2. This visit consisted of 4 health-related fitness assessments, including sit-up, push-up, flexibility and handgrip tests. Visits 3 and 4 consisted of measures of cardiovascular health at Hartford Hospital and the control visit. The cardiovascular health measures included body mass index (BMI), waist circumference, exhaled carbon monoxide (CO), vascular health (i.e., carotid intimal medial thickness and arterial stiffness), heart rate variability (HRV), resting BP, the maximum graded cardiopulmonary exercise stress test (GEST), and blood draws pre- and post-GEST to obtain SCD and CVD biomarkers. Firefighters were then attached to an ambulatory blood pressure (ABP) monitor and heart rate monitor for 24hr to assess ambulatory BP and HRV, respectively. Of note is that Visits 3 and 4 were conducted in random order so that study investigators could isolate the influence of the GEST on the ambulatory BP response to exercise from the control rest day. Randomization was performed using www.randomization.com. The control visit included measures of resting and ambulatory BP. In addition, subjects completed paper and pencil questionnaires on the topics of physical activity, nutrition, sleep, and mental health at this visit.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Subjects had to be full active duty firefighters employed by the local fire department in central Connecticut (CT).

- Subjects confirmed that they were taking the same medication for four weeks prior to Visit 1 and continued taking that medication throughout the duration of the study.

Exclusion Criteria:

- Subjects were excluded from the study if they were not able to comply with all study procedures as described in Visit 1, or in the event of injury or illness that would not enable them to participate.

- If subjects had resting blood pressure readings that were > 160 for systolic blood pressure and/or = 100 mmHg for diastolic blood pressure, they were excluded from the study and referred to their primary care physician for follow up.

- Subjects that were excluded from the study were not penalized in any way by the researchers or the administrators of the local fire department.

Study Design


Intervention

Behavioral:
GEST
On either Visit 3 or 4, subjects performed a maximal cardiopulmonary GEST following the Balke protocol. Immediately prior to the GEST, the study physician or his designee performed a brief physical examination, in which BP was assessed and all relevant medical information (i.e. medical history, medications, family history) were reviewed. The physician who completed the physical examination remained present during the GEST to monitor the subjects' electrocardiogram (ECG) and other physical signs. After the GEST was completed, the study physician reviewed the ECG for signs of ischemia. Breath-by-breath analysis of expired gases (i.e. oxygen and carbon dioxide) (ParvoMedicsTruneOne® 2400 Metabolic Measurement System, ParvoMedics Inc., Sandy, UT) determined maximal oxygen uptake (VO2max). Heart rate was measured continuously with a 12-lead ECG system and BP was measured by auscultation every 3 minutes during the GEST.

Locations

Country Name City State
United States Hartford Hospital Hartford Connecticut

Sponsors (2)

Lead Sponsor Collaborator
University of Connecticut Hartford Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Ambulatory Blood Pressure (ABP) Subjects were attached to an Oscar2 automatic noninvasive ABP monitor (Suntech Medical Instruments Inc., Raleigh, North Carolina, USA) on the nondominant arm to be worn until the next morning. The ABP monitor was programmed to record BP at regular intervals three times per waking hour and two times per sleeping hour. ABP was measured at the conclusion of Visits 3 and 4 during weeks 3 and 4.
Primary Change in Resting Blood Pressure Resting BP was measured according to the American Heart Association (AHA) standards using an automated BPTRU monitor (BPTRU Medical Devices, Coquilam, British Columbia, Canada). Subjects were seated for 5 minutes and then BP was measured three times, 1 minute apart in each arm. If the readings obtained were within 5 mmHg, these values were averaged and recorded as resting BP. If these readings did not agree within 5 mmHg, up to three additional readings were taken. If there were three readings obtained that agreed within 5 mmHg, these values were averaged and recorded as resting BP. If after the additional readings were taken and there were not three readings obtained that agree within 5 mmHg, the three closest values were averaged and recorded as resting BP. Resting BP was measured during Visits 3 and 4 during weeks 3 and 4.
Primary Change in Fasted Blood Sampling The fasting blood sampling occurred prior to and immediately after the GEST and was performed to obtain lipid-lipoprotein profiles and baseline biomarkers associated with cardiovascular disease. A trained phlebotomist collected five tubes of venous blood (52 cc or 3.5 tablespoons) from the antecubital vein of each subject. Serum total cholesterol (mg/dL), triglycerides (mg/dL), high-density lipoprotein cholesterol (HDL-C) (mg/dL), and low-density lipoprotein cholesterol (LDL-C) (mg/dL) were determined by colorimetric enzymatic assays. Serum glucose (mg/dL) was determined by enzymatic/spectrophotometric methods. The blood sampling occurred at Visit 3 or 4 during the GEST Visit during week 3 or 4.
Primary Change in Fasted Blood Sampling The fasting blood sampling occurred prior to and immediately after the GEST and was performed to obtain lipid-lipoprotein profiles and baseline biomarkers associated with cardiovascular disease. A trained phlebotomist collected five tubes of venous blood (52 cc or 3.5 tablespoons) from the antecubital vein of each subject. Serum insulin (uIU/mL) was determined by radioimmunoassay. The blood sampling occurred at Visit 3 or 4 during the GEST Visit during week 3 or 4.
Primary Change in Fasted Blood Sampling The fasting blood sampling occurred prior to and immediately after the GEST and was performed to obtain lipid-lipoprotein profiles and baseline biomarkers associated with cardiovascular disease. A trained phlebotomist collected five tubes of venous blood (52 cc or 3.5 tablespoons) from the antecubital vein of each subject. High sensitivity-C-reactive protein (mg/L) was determined by immunoturbidimetry. The blood sampling occurred at Visit 3 or 4 during the GEST Visit during week 3 or 4.
Primary Dietary Intake Usual dietary and alcohol intake were measured using the National Health and Nutrition Examination Survey (NHANES) semi-quantitative Food-Frequency Questionnaire. The NHANES Food Frequency Questionnaire is a validated tool for measuring dietary intake of both macro- and micro-nutrients based on 127 food items. Subjects were asked to self-report their average daily consumption of 124 food items. The data derived from the Food Frequency Questionnaire were coded and analyzed by members of the National Cancer Institute utilizing Diet*Calc software v1.4.3 (Bethesda, MD) in order to produce daily food frequency estimates of the 127 nutrient and dietary constituents. The Diet*Calc software analyzed Diet History Questionnaire data and generated nutrient and food group intake estimates from the Diet History Questionnaire. The questionnaire was filled out during Visit 3 or 4 at the Control Visit during week 3 or 4.
Primary Peak Oxygen Consumption VO2peak was measured by the maximal graded exercise stress test (GEST). The VO2peak test is the gold standard measure of cardiorespiratory fitness. The GEST took place either during Visit 3 or 4 during week 3 or 4.
Secondary Health-Related Fitness Assessments Subjects performed four health-related fitness assessments. The first assessment was the Flexibility test. All tests were performed with a one-minute rest between tests. The health-related fitness assessments were performed during study Visit 2 during week 2.
Secondary Health-Related Fitness Assessments Subjects performed four health-related fitness assessments. The second assessment was the Handgrip Strength test. All tests were performed with a one-minute rest between tests. The health-related fitness assessments were performed during study Visit 2 during week 2.
Secondary Health-Related Fitness Assessments Subjects performed four health-related fitness assessments. The third assessment was the Sit-Up test. All tests were performed with a one-minute rest between tests. The health-related fitness assessments were performed during study Visit 2 during week 2.
Secondary Health-Related Fitness Assessments Subjects performed four health-related fitness assessments. The fourth assessment was the Push-Up test. All tests were performed with a one-minute rest between tests. The health-related fitness assessments were performed during study Visit 2 during week 2.
Secondary Anthropometrics Height and weight were measured with a calibrated balance beam scale to calculate body mass index (BMI) (kg·m2). Anthropometrics were measured during Visit 3 or 4 during the GEST Visit during week 3 or 4.
Secondary Anthropometrics Waist circumference (cm) was measured at the iliac crest using a non-distensible Guilick tape measure. Anthropometrics were measured during Visit 3 or 4 during the GEST Visit during week 3 or 4.
Secondary Carotid-Intima Media Thickness (cIMT) Subjects rested in the supine position for 5 minutes. CIMT was measured using doppler ultrasound on the carotid arteries at three sites (common, bulb, and internal bilateral). The artery will be imaged using a 5- to 12-MHz multifrequency linear-array transducer attached to a high-resolution ultrasound machine (Terason t3000; Burlington, MA). The image will be digitized and edge detection software (Carotid Analyzer; Medical Imaging Applications, Inc.) will then be used to trace the lumen-intima and intima-medial boundaries of the artery over a 1 minute clip to calculate the average intima-medial thickness at three sites. Mean and maximal distances will be compared to established norms by age, sex/gender, and race/ethnicity. CIMT was measured during Visit 3 or 4 during the GEST Visit during week 3 or 4.
Secondary Change in Arterial Stiffness Assessment The CPV system (SphygmoCor® CPV Central Blood Pressure/Pulse Wave Velocity System) measured pulse wave velocity (PWV). PWV gives an indication of central arterial parameters. Briefly, the subjects rested in the supine position for 10 minutes. After this rest period, central PWV measures (carotid-femoral), and PWA (radial) were made. Arterial stiffness was measured during Visit 3 or 4 during the GEST Visit during week 3 or 4.
Secondary Change in Resting Heart Rate Variability (HRV) The resting HRV assessment was performed in a quiet, low-light and temperature-controlled room in the supine position after a 5 min rest period using the GE Case Exercise Testing System (GE Healthcare, Wauwaposa, WI). Following the resting period, electrocardiogram (ECG) RR intervals will be measured in the supine position for 5 min. During these measurements, the subject's breathing frequency was paced at 12 breaths•min-1 with the aid of a metronome. Resting HRV was measured during Visit 3 or 4 during the GEST Visit during week 3 or 4.
Secondary Change in Ambulatory HRV Subjects were fitted for a Polar® V800™ HR monitor for the ambulatory HRV assessment for 24 hr. An elastic HR belt was placed below the chest muscles with conductive gel and applied as described by the manufacturer. RR intervals were recorded with a resolution of 1ms and captured by the receptor belt and stored by a wrist watch receiver under free living conditions without controlling for respiratory rate or tidal volume. Ambulatory HRV was measured during Visit 3 or 4 during the GEST Visit during week 3 or 4.
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04098172 - Evaluate the Performance and Safety of Comet Pressure Guidewire in the Measurement of FFR N/A